OPEX® Corporation Offers a Simplified, One-Touch Document Scanning Solution with the Introduction of Axis™

 (BUSINESS WIRE)--OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of Axis™, a new document scanner that brings the benefits of one-touch scanning to a simplified, single-bin configuration. Designed for document capture workflows where minimal document preparation, mixed media handling or operational simplicity are priorities, Axis bridges the gap between OPEX’s desktop scanner series and its multi-bin production scanner portfolio.

“We developed Axis in direct response to market demands,” said Dann Worrell, President, Document and Mail Automation, OPEX. “Our customers want to simplify their scanning processes, reduce operating costs, and improve quality. Axis delivers on these priorities by combining our minimal-prep, One-Touch scanning technology with a single-bin design. With a lower market accessible entry point, Axis helps customers process documents more efficiently while achieving more consistent results.”

OPEX’s newest solution is built on a production-class transport architecture, supporting both continuous batch scanning and scan-from-folder workflows on a single platform. It manages auto feed and drop feed, and handles mixed sizes, weights and conditions. Capable of scanning up to 120 ppm, Axis is designed for any scanning operation that handles mixed document types and spends more significant hours prepping documents before scanning. It is ideal for businesses looking for simplified deployment, flexible workstation options, and a focused, purpose-built alternative to multi-bin production systems.

Axis is available in two models to support varying deployment requirements. The Axis includes an integrated workstation with system component mounts, while the AXIS-M (mobile) offers a foldable support structure designed for relocation between work areas or sites.

“Our team is always focused on building new solutions that enable all types of businesses to improve workflow, drive efficiencies, and solve challenges,” said Scott Maurer, President, International Division, OPEX. “Axis represents the midpoint in our document scanning portfolio, providing a cost-effective approach for advanced document capture applications when physical sorting and dedicated, MICR-based payment processing aren’t required.”

The Axis document scanner enables operators to capture documents with a streamlined, one-touch process, reducing manual handling and improving productivity. Axis supports scan-on-demand, overflow, and distributed capture operations, without requiring workflow-specific scanner configurations. With its single output design, Axis is well suited for archive, backfile conversion, and folder-based scanning applications, where documents are captured and returned in their original order. Additional features include an integrated 22” touchscreen display, a rescan feeder, a document conditioning roller, ultrasonic sensors to detect multi-feed conditions, and more.

Axis joins the existing portfolio of advanced document scanning solutions at OPEX, which includes Falcon®+, Falcon®+ RED™, Gemini®, and Velo™ Powered by Inotec®. It is the first OPEX-designed hardware platform to support a customer-supplied PC Controller and planned TWAIN connectivity, expanding deployment flexibility and integration options while maintaining compatibility with OPEX workflows.

OPEX will debut Axis at ARMA InfoCon 2026, scheduled from October 25 through 28, at the Savannah Convention Center in Georgia, with live demonstrations in Booth #803. Axis will also be available for demonstration at our world headquarters in Moorestown, NJ, and EMEA headquarters in Duisburg, Germany.

About OPEX

OPEX® Corporation is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has over 1,600 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and in the future. For more information, visit opex.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261006807452/en/

Permalink

https://www.aetoswire.com/en/news/54616480

Contacts

For Additional Information

Laura Evans

levans@opex.com

+1.856.727.1100 x 5012

 

illumynt Launches Talorem®, Bringing Engineering Rigor to Smarter Technology Reuse

 COLUMBUS, Ohio -

Proprietary technology platform delivers faster receiving, better asset intelligence, more accurate grading and higher recovery value.

(BUSINESS WIRE) -- illumynt, a technology-driven lifecycle management company serving AI infrastructure, hyperscale, OEM and enterprise environments, today announced the launch of Talorem®, its proprietary technology platform designed to bring greater precision, intelligence and recovery value to the management of advanced computing assets.

Talorem is illumynt’s proprietary technology platform for engineering-grade testing, refurbishment, recovery, grading and asset intelligence at scale. As the technology foundation behind illumynt’s advanced computing lifecycle operations, Talorem brings together OEM-grade testing and qualification, clean room component recovery, centralized grading infrastructure and analytics to create greater intelligence at every stage of the asset lifecycle-enabling faster processing, more accurate grading and higher recovery value.

“Talorem represents how we believe technology lifecycle management needs to evolve,” said Jörg Herbarth, CEO of illumynt. “The more precisely we can identify, test and understand an asset, the better decisions we can make about its next use—and the more value we can recover for our customers.”

The Engineering Rigor Behind Smart Reuse

As infrastructure becomes more complex and refresh cycles accelerate, traditional approaches to IT asset disposition can be limited by manual processes, generalized testing and incomplete asset data. Talorem applies engineering-grade methodology and standardized processes to determine whether technology should be redeployed, repaired, remarketed, harvested for high-value components or responsibly recycled.

Just as importantly, Talorem creates structured asset data throughout the process. As more equipment is processed, that intelligence builds over time, creating more accurate benchmarks, supporting more defensible recovery pricing and enabling lifecycle decisions grounded in observed asset performance rather than assumptions.

Built for the Economics of Advanced Computing

For hyperscalers, OEMs and enterprises, the economics of technology disposition are changing. Hardware is becoming more specialized, individual components can retain significant value even when a larger system reaches end of life, and accurate testing and grading can materially affect decisions around reuse, resale and recovery.

Talorem is built around that reality, combining engineering discipline with asset intelligence to help organizations understand not simply what an asset is, but what it can still do and what it is still worth.

“Circularity is increasingly an engineering and data challenge, not simply a logistics challenge,” Herbarth added. “Talorem gives us the ability to make smarter reuse and recovery decisions at scale while giving our customers greater visibility into the condition and value of their technology.”

About illumynt

illumynt is a technology-driven lifecycle management company helping organizations maximize the value of complex IT and advanced computing infrastructure. Through engineering-grade diagnostics, repair, component recovery, secure processing and asset intelligence, illumynt helps hyperscalers, OEMs and enterprises extend technology lifecycles, recover greater value and make more informed infrastructure decisions.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261006382527/en/

Permalink

https://www.aetoswire.com/en/news/0610202657856

Contacts

Alyson Kaye

Alyson.kaye@illumynt.com

617.407.6381

 

30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation

 ZUG, Switzerland - Tuesday, 06. October 2026 AETOSWire  

Galderma celebrates the 30th anniversary of Restylane, its pioneering range of hyaluronic acid (HA) injectables that established the category as the first to market1

With three decades of innovation across technology, packaging, and treatment areas, Restylane continues to meet growing aesthetic needs, including emerging areas such as medication-driven weight loss, skin quality and menopause1-11

This year’s milestones include the approvals of Restylane Shaype™ in the European Union (EU) for enhancement of the chin region, the new state-of-the-art Restylane syringe in the EU, United States (U.S.), and Canada, and Restylane Volyme™* in the U.S. for temple hollowing, with a dual-layer patent-pending technique leveraging both needle and cannula12-18

With more than 80 clinical trials, 180 publications, around 407,000 patients evaluated for safety, and 77 million treatments administered worldwide, Restylane remains a pioneer in science-backed aesthetic innovation and continues to shape the future of HA injectables1-3,19,20

 

(BUSINESS WIRE) -- Galderma (SIX: GALD), the pure-play dermatology category leader, celebrates 30 years since Restylane was launched in Europe as the first hyaluronic acid (HA) injectable.1 With HA closest to the skin’s own, Restylane is designed to deliver personalized, natural-looking outcomes that meet diverse patient needs across key areas of the face, décolletage, and hands.8,10,12,21-31 With three decades of innovation across technology, packaging, and treatment areas, Restylane remains at the forefront of innovation, evolving from its original NASHA®, technology into a comprehensive portfolio spanning three distinct technologies: NASHA HD™, NASHA®, and OBT™.1,8,21,22 Together, these technologies offer solutions ranging from firmer gels that provide contouring and structural support, to soft, flexible formulations that smooth facial lines and wrinkles for a more youthful look.8,12,21-31

The Restylane portfolio has most recently achieved EU Medical Device Regulation certification for the products created with NASHA HD™, NASHA®, and OBT™ technologies.12,23-29 As one of the world's most rigorous medical device regulatory frameworks, the certification reinforces confidence in the strong safety profile, quality standards and scientific foundation behind the portfolio.32

   

 “Restylane's 30-year journey is a testament to Galderma's enduring commitment to science-led innovation in aesthetics. Supported by extensive clinical experience – including more than 400,000 patients evaluated for safety – and robust real-world data, Restylane has helped define aesthetics, setting a high standard for safety, efficacy and natural-looking results since it launched as the first HA injectable three decades ago. With market penetration still relatively low, significant opportunities remain to expand adoption, and as we look to the future, we will continue to build on this foundation through innovation that reinforces the essential role of HA injectables in the future of aesthetics.”

BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.

GLOBAL HEAD OF R&D

GALDERMA

 

   

Expanding Restylane’s versatility to support tailored aesthetic outcomes

Restylane continues to expand treatment possibilities through new technologies, indications, and devices.

Restylane Shaype was recently approved in the EU for correction and enhancement of the chin region.12 Powered by Galderma’s new NASHA HD™ technology, it is the firmest HA injectable gel available among facial filler market leaders, delivering a unique bone-mimicking effect that enables immediate, natural-looking structural enhancement in the lower face.12,21,33 Restylane Shaype is the first minimally invasive injectable aesthetic option to provide structure in this increasingly important treatment area, which has previously largely relied on surgical implants.21

A new state-of-the-art Restylane syringe was also approved in the EU, U.S. and Canada earlier this year, for use with the NASHA® lidocaine Restylane products in multiple facial indications.13-15 It was designed in collaboration with over 70 aesthetics practitioners to be optimized for ergonomic functionality, ease of aspiration, and ease of operation.34-37 It has compact blister-free packaging that is 100% recyclable and reduces in-clinic waste by up to 30% based on volume reduction.38,39 A survey of over 300 healthcare professionals in Brazil who had personal experience using the Restylane syringes found that 89% preferred the next-generation syringe over the standard syringe.40 The next-generation syringe complements Galderma’s patented SmartClick™ syringe for Restylane Skinboosters™, which monitors each micro-dose, allowing injectors to focus on technique ​and placement for enhanced patient safety, precision and control.31,41

As global demand grows for treatments that address the evolving effects on the skin of aging, menopause, and weight loss, Restylane Volyme received U.S. approval in March for the correction of temple hollowing with a dual-layer patent-pending technique leveraging both needle and cannula.16-18 Temple volume loss can disrupt facial balance and harmony, and contribute to a tired, sunken, and aged appearance, a challenge increasingly seen in people undergoing medication-driven weight loss and experiencing age- and hormone-related changes, including menopause.6,18,42

   

 “Restylane has been a trusted part of my practice for many years, thanks to the constant innovations brought to the portfolio in terms of product, indications and even packaging. Today, I treat an increasingly diverse range of individuals seeking personalized, natural-looking results, so having a versatile portfolio that goes beyond volumizing and can provide lift, contour, definition and skin quality improvements across multiple areas of the face and body is invaluable. Supported by decades of science, Restylane gives me the confidence to tailor treatments to each patient’s unique anatomy, goals and stage of life.”

DR. LUDDI LUIZ OLIVEIRA

PLASTIC SURGEON

BRAZIL 

 

   

Restylane expands access to injectable aesthetics for new patient segments

Restylane remains highly relevant in addressing some of today’s most significant aesthetic trends and needs including medication-driven weight loss, menopause and skin quality.

Interim results from an investigator-initiated trial showed that combining Restylane Skinboosters with Sculptra® – the first proven regenerative biostimulator – drove progressive improvements in hydration, skin barrier function, and overall skin quality in menopausal women.4,43-46 These results are reinforced by consensus guidelines concluding that Restylane Skinboosters can complement Sculptra in the décolletage for comprehensive body rejuvenation.47

Additionally, Restylane also has an important role in addressing the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss.11 The combination of Restylane Lyft™ or Volyme with Sculptra has been shown to deliver visible improvements in skin quality and significantly enhance patient satisfaction and emotional wellbeing.11

Supported by 30 years of innovation and more than 77 million treatments administered worldwide, Restylane has helped define the HA injectable category and continues to shape the future of aesthetic medicine.1-3 With more than 80 clinical trials, 180 publications and around 407,000 patients evaluated for safety, its legacy is built on extensive scientific evidence and clinical experience.3,19 These milestones demonstrate Galderma’s ongoing commitment to using its unique dermatology expertise and strong portfolio to meet the needs of patients and healthcare professionals today and tomorrow.

*Restylane Volyme is known as Restylane Contour™ in the U.S.

About the Restylane portfolio

Restylane HA treatments are designed differently to go beyond volumizing for natural-looking results.2,24,48 Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.7,10,49 Powered by NASHA HD™, NASHA®, and OBT™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.8,21,22,33 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results.2,50,51 Approved indications vary by market.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.

Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.

Galderma. Data on file. MA-55607. Restylane® 27 years data publications analysis.

Nikolis A, et al. A comprehensive interim analysis of skin hydration, barrier function (TEWL), elasticity, and patient satisfaction across two treatment arms. Interim Data on File. April 2026.

Nikolis A, et al. Evaluating the role of small particle hyaluronic acid fillers using micro-droplet technique in the face, neck and hands: a retrospective chart review. Clin Cosmet Investig Dermatol. 2018;11:467–475. doi: 10.2147/CCID.S175408.

Humphrey CD & Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-72.

Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.

Belmontesi M, et al. Injectable non-animal stabilized hyaluronic acid as a skin quality booster: An expert panel consensus. J Drugs Dermatol. 2018;17(1):83– 88.

Kim J. Effects of injection depth and volume of stabilized hyaluronic acid in human dermis on skin texture, hydration, and thickness. Arch Aesthet Plast Surg. 2014;20:97-103. doi:10.14730/aaps.2014.20.2.97.

Galderma. Data on file. MA-58650. Degree of modification of HA fillers.

Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label study to evaluate the synergistic effects of biostimulator and dermal fillers for cheek augmentation and correction of contour deficiencies: Nine-month topline results.

Restylane® Shaype EU IFU.

Galderma. Data on file. U.S. FDA Restylane syringe PMA supplement approval letter.

Galderma. Data on file. Health Canada Restylane Medical Device License.

Galderma. Data on file. Dekra Restylane next generation syringe report.

Restylane® Contour™. US IFU.

Galderma. Data on file. MA-63365 Study Report. 2025.

Galderma. Data on file. Restylane Contour temple investigator closeout meeting executive summary. 2025.

Park KE, et al. Response of 21 hyaluronic acid fillers to recombinant human hyaluronidase. Plast Reconstr Surg Glob Open. 2023;11:e5457. doi:10.1097/GOX.0000000000005457.

Verpaele A, Strand A. Restylane SubQ, a non-animal stabilized hyaluronic acid gel for soft tissue augmentation of the mid-and lower face. Aesthetic Surg J. 2006;26(Suppl.):S10–17. doi: 10.1016/j.asj.2005.09.009.

Nikolis A, et al. Effectiveness and safety of a new hyaluronic acid injectable for augmentation and correction of chin retrusion. J Drugs Dermatol. 2024;23(4):255–61. doi: 10.36849/JDD.8145.

Öhrlund Å, et al. Differentiation of NASHA and OBT hyaluronic acid gels according to strength, flexibility, and associated clinical significance. J Drugs Dermatol. 2024;23(1):1332–6. doi: 10.36849/JDD.7648.

Restylane® Lyft™. EU IFU.

Restylane® Classic. EU IFU.

Restylane® Eyelight™. EU IFU.

Restylane® Defyne™. EU IFU.

Restylane® Volyme™. EU IFU.

Restylane® Kysse™. EU IFU.

Restylane® Refyne™. EU IFU.

Restylane® Skinboosters Vital Lidocane™. EU IFU.

Restylane® Skinboosters Vital Light Lidocane™. EU IFU.

European Medicines Agency. Available online. Accessed October 2026.

Galderma. Data on file. MA-56724. 2023. Global rheology data (xStrain and G´ including Restylane SHAYPE).

Galderma. Data on file. MA-64737.

Galderma. Data on file. MA-56005.

Galderma. Data on file. Design and development of the next generation syringe.

Galderma. Data on file. MA-59168.

Galderma. Data on file. Vimer S.r.l. Declaration of recycling compliance. 2025.

Galderma. Data on file. MA-63907.

Galderma. Data on file. Restylane next generation syringe HCP survey.

Landau M, Fagien S. Science of Hyaluronic Acid Beyond Filling: Fibroblasts and Their Response to the Extracellular Matrix. Plast Reconstr Surg. 2015;136(5S):188S–195S. doi: 10.1097/PRS.0000000000001823.

Qin J. Ozempic face: A new challenge for facial plastic surgeons. JPRAS. 2023;81:97-98. doi: 10.1016/j.bjps.2023.04.057.

Galderma. Data on File. MA-60875. A Single Center, Double-Blinded, Split-Body, Randomized Clinical Trial of Injectable Poly-L-Lactic Acid for Volumization and Adipogenesis of the Hip Dell.

Huth S, et al. Molecular Insights into the effects of PLLA-SCA on Gene Expression. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.7791.

Waibel J, et al. A randomized, comparative study describing the gene signatures of poly-l-lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS 2024, February 1-3, 2024, Paris, France.

Sculptra®. EU Instructions for Use. 2025. Available online. Accessed October 2026.

Haddad A, et al. International consensus: Sculptra®/Restylane® Skinboosters™ for non-facial rejuvenation. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

Galderma. Data on file. MA-48544 Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021.

Kablik J, et al. Comparative physical properties of HA dermal fillers. Dermatol Surg. 2009; 35, 302–312. doi: 10.1111/j.1524-4725.2008.01046.x.

Solish N, et al. Dynamics of HA fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.

Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.1320.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261005211995/en/

Permalink

https://www.aetoswire.com/en/news/0610202657830

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com

+41 76 210 60 62

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

Invivoscribe® Advances Molecular Clonality Testing Portfolio with Comprehensive LymphoTrack® Flex Suite

  SAN DIEGO - Tuesday, 06. October 2026 AETOSWire Print 

New ultra-high sensitivity tests enable objective, automation-ready, high-throughput clonality and MRD workflow.

 

(BUSINESS WIRE)--Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the complete LymphoTrack Flex suite, an integrated next-generation sequencing (NGS) solution to identify and track immunoglobulin and T-cell receptor gene rearrangements.

As NGS-based immune receptor MRD analysis moves from academic laboratories into routine use in oncology research centers, the demand for standardized, high-throughput workflows is accelerating. Laboratories are seeking both greater efficiency and ultra-high sensitivity. This requires increasing DNA inputs while ensuring higher testing throughput and analytical performance. Translational programs need testing that is both reproducible and scalable across sites. LymphoTrack Flex meets these demands, bringing seven molecular targets (IGHV leader, IGH FR1, IGH FR2, IGH FR3, IGK, TRB and TRG), together in one automation-ready workflow with massively parallel multiplexing and a powerful bioinformatics engine to provide objective analyses and tracking of clonal sequences.

“Clonality, somatic hypermutation, and measurable residual disease provide complementary molecular insights across the course of lymphoid malignancies, with growing relevance as treatment approaches evolve beyond fixed-duration therapy toward more dynamic, MRD-informed strategies,” said Brad Patay, Chief Medical Officer of Invivoscribe. “LymphoTrack Flex enables laboratories to characterize clonal populations at baseline and select sequence-specific clonotypes for longitudinal assessments, providing a consistent molecular picture of disease over time to support the evaluation of these evolving treatment approaches.”

The software portfolio provides flexibility across laboratory environments. LymphoTrack Software supports local, desktop-based analysis for labs that want to run testing independently on a single workstation. LymphoTrack Enterprise Software provides a centralized environment for high-throughput analysis, standardized reporting, and integration with laboratory and data infrastructures, enabling labs to scale testing volume without re-architecting laboratory workflow.

“Our vision is to give all laboratories access to optimized MRD assays, controls, and analysis software, with one standardized approach,” said Jeff Miller, CEO of Invivoscribe. “I am incredibly proud of the team behind LymphoTrack Flex. This release is the result of decades of multidisciplinary and international clinical laboratory experience.”

With the complete LymphoTrack Flex suite now available, laboratories can implement a flexible, scalable NGS workflow for clonality assessment, somatic hypermutation analysis, and sequence-based MRD research across a broad range of lymphoid malignancies. Laboratories ready to expand or standardize their NGS clonality and MRD capabilities can learn more at LymphoTrack Flex page or contact inquiry@invivoscribe.com to connect with an Invivoscribe specialist.

About Invivoscribe

Invivoscribe is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For more than thirty years, Invivoscribe has advanced the quality of healthcare worldwide by delivering high-quality, standardized reagents, diagnostic assays, sample preparation systems, and bioinformatics solutions that support precision medicine. The company has a proven track record of partnering with pharmaceutical and biotechnology organizations to support clinical trial testing through its global laboratory network in the United States, Germany, Japan, and China, as well as to develop and commercialize companion diagnostics, leveraging deep expertise in regulatory strategy and laboratory services. By offering both distributable diagnostic kits to over 700 clinical laboratory customers and clinical testing services through its globally located clinical laboratory subsidiaries, LabPMM®, Invivoscribe is an ideal partner across the full diagnostic lifecycle - from development and clinical trials through regulatory submission and commercialization.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261006900484/en/

Permalink

https://www.aetoswire.com/en/news/54616964

Contacts

For more information, visit www.invivoscribe.com, or contact inquiry@invivoscribe.com

 

Posiflex Unveils AI-Powered SCO Series Kiosk to Accelerate the Future of Self-Service Retail

 

TAIPEI, Taiwan -

A modular, smarter self-checkout platform engineered for weighing, RFID, and loss-prevention automation across diverse retail environments

(BUSINESS WIRE) -- Posiflex Technology, Inc., a global leader in Point of Sale (POS) systems and Online-to-Offline (O2O) solutions, proudly introduces the SCO Series Self-Service Kiosks, an AI-powered platform designed to redefine self-service retail by offering flexible system configurations that support either precise weighing-scale transactions or RFID-enabled automated checkout.

Built to address the evolving needs of both traditional fresh-goods environments and modern RFID-driven retail concepts, the SCO Series enables retailers to elevate operational accuracy, accelerate checkout processes, and future-proof store deployments through modular architecture, intelligent automation, and adaptable form factors engineered for next-generation retail.

AI-Enabled Self-Checkout Solution for Weighing & RFID Applications

Designed for diverse retail environments, the SCO Series offers two dedicated configurations: a weighing-scale model for fresh and bulk goods and an RFID model for tag-enabled retail.

The weighing solution delivers fast and accurate pricing for fruits, vegetables, and bulk items, featuring a durable stainless-steel platform, seamless POS integration, and real-time weight display to ensure precise, efficient self-checkout.

The RFID configuration enables automatic item identification and multi-item contactless reading without barcode alignment, accelerating checkout while improving operational efficiency for apparel, specialty retail, and unattended store applications.

AI-Powered Loss Prevention for an Optimized Checkout Experience

At the core of the platform, AI-driven object recognition reduces manual input, minimizes mis-scanning, and supports behavior anomaly detection. Optional AI loss-prevention capabilities and a large LED status indicator provide real-time alerts, helping retailers easy monitoring, prevent scanning error, and maintain efficient checkout operations.

Modular and Scalable Design for Flexible Deployment

The SCO Series features a modular design that adapts to diverse retail environments and store layouts. Retailers can configure optional modules such as weighing scales, RFID detection, and payment peripherals, including MSR, NFC/RFID readers, and a dedicated EMV mounting bracket.

Powered by flexible Intel® platform options, the system delivers scalable performance for cost-effective deployment from pilot projects to large-scale rollouts.

Flexible Display Installation for User-Centric Design

The SCO Series features a 15.6-inch true-flat PCAP touch display with an optional 10-inch customer-facing display for enhanced engagement. To suit different store layouts, the main display can be installed on either the left or right side, supporting countertop, kiosk, and full-standing deployments.

Developer Tools & Seamless System Integration

Posiflex provides a comprehensive Software Development Kit (SDK) with developer documentation and integration tools, enabling partners to integrate with existing POS systems, build customized workflows, and support advanced features such as AI object recognition and AI loss prevention. This flexible development framework accelerates deployment while supporting evolving retail needs.

Expanding its self-service portfolio, the Posiflex SCO Series now supports floor-standing and countertop deployments, as well as the Datalogic MAGELLAN™ 9600i Module support. A dedicated weighing scale model is also scheduled for release soon, broadening the solution's suitability for supermarkets, grocery stores, and other retail environments.

The Posiflex SCO Series self-service kiosks empower retailers to modernize customer journeys, strengthen operational control, and deliver frictionless checkout experiences in today's rapidly evolving retail landscape.

Learn more about SCO Series, please visit the product landing page: https://www.posiflex.com/promotion/self-checkout-solutions-SCO-series/

About POSIFLEX Group

Posiflex Group is a global leader in Commercial AIoT platform powered by smart Online-to-Offline (O2O) and Scenario-defined Embedded Appliance Solutions. Pillared by three brands, Posiflex Group consists of Posiflex as a global top-5 brand in POS & Kiosk, Portwell as Embedded Foundry for AIoT Edge Compute, and KIOSK Information Systems (KIS) for managed self-service automation – together with a common mission to enable optimized productivity and superior customer journey across the connected world.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261004628458/en/

Permalink

https://aetoswire.com/en/news/0610202657829

Contacts

Media Contact:

Jessie Hsu, Marketing Director, Global Marketing Division

jessiehsu@posiflex.com

 

New Global Survey Finds Majority of VMware Users Are Choosing Alternative Paths for Cost Control, Roadmap Flexibility and Better Support

LAS VEGAS - Tuesday, 06. October 2026

Rimini Street and DBTA/Unisphere Research survey finds 66% are already using or are considering third-party support

(BUSINESS WIRE) -- Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced findings from the 2026 IT Virtualization Survey – What’s Next for VMware Users, a new global survey of nearly 300 VMware user organizations conducted by Unisphere Research on behalf of Rimini Street.

Cost Cited as the Number One Factor in Seeking Alternative VMware Solutions

Key Findings: 90% of respondents said they are considering alternatives to VMware due to higher licensing costs, while 54% cited the end of perpetual license support as another reason to evaluate other options.

The research shows that cost remains the leading driver of virtualization roadmap decisions, with nearly three-quarters of respondents (73%) citing cost savings as a top priority. At the same time, organizations reported significant barriers to progress, including operational complexity (40%), multi-vendor management challenges (38%), securing the increased attack surface (37%) and team skills requirements (37%).

These findings suggest that while organizations are actively pursuing change, they are also looking for ways to reduce risk and avoid unnecessary disruption.

IT Leaders Choose Multiple and Hybrid Hypervisor Models for Greater Control and More Flexibility

Key Findings: 60% are considering a multiple-hypervisor strategy, reflecting growing interest in more flexible, mixed environments that support both operational and financial goals. In addition, 47% are favoring a hybrid IT virtualization environment consisting of hypervisors and containers for "best of both worlds" workload placement.

The findings also suggest that many organizations are considering a range of options beyond VMware Cloud Foundation (VCF). Nearly half of respondents (48%) said they do not currently plan to move any of their assets to VCF, indicating that many enterprises are taking a more measured approach and prioritizing strategies that align with their business needs, existing investments and operating models.

The trend shows increasing diversification in enterprise virtualization strategies with a longer-term transition toward bespoke, multi-platform IT virtualization environments. As organizations reevaluate their paths to modernization, they are increasingly adopting approaches that combine on-premises infrastructure, private cloud, public cloud and alternative hypervisors to support workload flexibility, operational efficiency and better cost control.

Majority of VMware Customers Consider Third-party Support to Protect and Extend the Life of VMware Investments

Key Findings: 66% of respondents are currently using or considering third-party support. Leading reasons cited include security (60%), installation and implementation support (57%), and service and support concerns (54%).

IT security leaders report being overwhelmed by the “vulnerability treadmill.” In virtualized IT environments, a single compromised virtual machine can expose hundreds of guest machines, increasing the risk of service outages and potential data breaches. This makes the hypervisor a high-value target for ransomware and advanced persistent threats.

As VMware customers reassess their virtualization strategies, many are exploring third-party VMware support to strengthen service coverage, maintain operational continuity and extend the value of existing investments. The findings suggest organizations want greater control over how they secure, support and evolve environments.

Further, 77% of IT virtualization security leaders said they would see value in a security solution that provides real-time threat visibility and proactive protection against vulnerabilities, rather than relying solely on Broadcom’s patching program. Together, these findings point to growing demand for more resilient, security-by-design virtualization strategies.

“The shift for current VMware users is not simply about replacing one vendor with another. It reflects a broader effort by enterprises to reduce dependency on a single provider, maintain continuity for mission-critical systems and modernize at a pace that fits their own business requirements,” cited Joe McKendrick, lead analyst, Unisphere Research. “For many organizations, that means balancing support for existing environments with new investments designed to improve resilience, security and scalability over time.”

“Organizations want more choice, flexibility and control over their virtualization strategies,” said Keith Costello, EVP and chief operating officer, Rimini Street. “Our suite of services for VMware helps clients reduce costs, strengthen security, improve support outcomes and extend the value of their existing VMware investments — without being forced into disruptive timelines or one-size-fits-all vendor roadmaps. These survey findings reinforce the need for practical, vendor-independent strategies that put business priorities back on the client’s terms.”

Access the full report, 2026 IT Virtualization Survey – What’s Next for VMware Users, available for download.

Survey methodology

The survey was conducted by Unisphere Research in partnership with Rimini Street. Unisphere Research is the market research unit of Unisphere Media, a division of Information Today, Inc., publishers of Database Trends and Applications magazine and the 5 Minute Briefing newsletters. It surveyed 269 executives, managers and professionals across VMware user organizations between December 2025 and February 2026 to assess current usage, future plans and perceptions of VMware under Broadcom, as well as interest in alternative solutions. All respondents were current users of VMware solutions at the time the survey was conducted.

About Rimini Street, Inc.

Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a proven, trusted global provider of end-to-end, mission-critical enterprise software support, managed services and innovative Agentic AI ERP solutions, and is the leading third-party support provider for Oracle, SAP and VMware software. The Company has signed thousands of IT service contracts with Fortune Global 100, Fortune 500, midmarket, public sector and government organizations who have leveraged the Rimini Smart Path™ methodology to achieve better operational outcomes, billions of US dollars in savings and fund AI and other innovation.

To learn more, please visit www.riministreet.com, and connect with Rimini Street on X, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “anticipate,” “assume,” “believe,” “budget,” “continue,” “could,” “currently,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “outlook,” “plan,” “possible,” “goal,” “potential,” “predict,” “project,” “reflect,” “results,” “seem,” “seek,” “should,” “will,” “would” and other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to our ability to attract new clients or retain and/or sell additional products or services to existing clients; our ability to achieve and maintain an adequate rate of revenue growth; cost of revenue, including changes in costs associated with our efforts to grow and the results of any efforts to manage costs to align with current revenue expectations and the expansion of our offerings; the effects of increased intense competition in our industry and our ability to compete effectively; our ability to successfully educate the market regarding the advantages of our support and managed services for ERP software and to sell the products and services comprising our “Rimini Smart Path™” solutions portfolio, including but not limited to our Agentic AI ERP solutions; our intentions with respect to our pricing model and expectations of client savings relative to use of other providers; the evolution of the ERP software management and support landscape facing our clients and prospects; estimates of our total addressable market; the effects of seasonal trends on our results of operations, including the contract renewal cycles for vendor-supplied software support and managed services; the effects of the efforts of enterprise software vendors to sell upgrades or migrations to cloud-based versions of their enterprise software on our results of operations; our ability to scale our operations quickly enough to meet our clients’ changing needs or decrease our costs adequately in response to changing client demand; risks arising from incorporating artificial intelligence (“AI”) technologies into our products or services or any deficiencies associated with AI technologies used by us or by our third-party vendors and service providers; our ability to maintain, protect, and enhance our brand; the loss of one or more members of our management team and our ability to attract and retain additional qualified technical, sales and marketing personnel; our ability to expand our marketing and sales capabilities; our ability to avoid interruptions to, or degraded performance of, our services and the impact of any such interruptions or performance problems on our operations; our ability to defend against cybersecurity threats and to comply with data protection and privacy regulations; our expectations regarding new product offerings, innovation solutions, partnerships and alliance programs and our ability to develop and maintain strategic partnerships; our ability to expand internationally and the risks associated with global operations; our wind down of support services for Oracle’s PeopleSoft software products and the impact on future period revenue and costs incurred related to these efforts; the continuing impact of and our ability to comply with the terms of our July 2025 settlement agreement with Oracle; the impact of macro-economic trends, including inflation and changes in foreign exchange rates, as well as general financial, economic, regulatory and political conditions affecting the industry in which we operate and the industries in which our clients operate; our ability to generate significant capital through our operations or to raise additional capital necessary to fund and expand our operations and invest in new services and products; our business plan and our ability to effectively secure and manage our growth and associated investments; risks relating to retention rates, including our ability to accurately predict retention rates; our ability to protect our intellectual property; our ability to maintain an effective system of internal control over financial reporting; changes in laws or regulations, including tax laws or unfavorable outcomes of tax positions we take; tariff costs; our ability to realize benefits from our net operating losses; any negative impact of environmental, social and governance (“ESG”) matters on our reputation or business and the exposure of our business to additional costs or risks from our reporting on such matters; our credit facility’s ongoing debt service obligations and financial and operational covenants on our business and related interest rate risk; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the volatility of our stock price; the amount and timing of repurchases, if any, under our stock repurchase program and our ability to enhance stockholder value through such program; our ability to maintain our good standing with the United States and international governments and capture new contracts with public sector entities; the occurrence of catastrophic events that may disrupt our business or that of our current and prospective clients; future acquisitions of, or investments in, complementary companies, products, subscriptions or technologies; and those discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on July 30, 2026, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the U.S. Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.

© 2026 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261006014490/en/

Permalink

https://www.aetoswire.com/en/news/0610202657859

Contacts

Janet Ravin

VP, Corporate Marketing

Rimini Street, Inc.

+1 702 285-3532

pr@riministreet.com

Cities integrating AI into public services with no common framework for assessing readiness, Oxford Insights finds

 London, United Kingdom - Tuesday, 06. October 2026 AETOSWire Print 

Organisation behind the Government AI Readiness Index proposes a City AI Readiness Index, based on a new study of Abu Dhabi

 

Cities are integrating artificial intelligence into public services and operations with no shared framework for measuring or comparing how prepared they are to do so safely, effectively or accountably.

Existing global indices compare countries on legislation, investment and research output, but the AI efforts happening at city level – the level of government where the technology most directly shapes daily life – are not systematically captured.

To start closing that gap, Oxford Insights researchers studied AI readiness across six cities. They found that all share the same core priorities, from governance and funding to talent and infrastructure, but take distinct routes to AI readiness, shaped both by structural conditions and by deliberate strategic choices.

The findings draw on an in-depth study of Abu Dhabi, where researchers were able to observe city-level AI readiness being actively built rather than planned.

The UAE capital was considered alongside five further international cities: Seoul, London, Montreal, Helsinki and Tallinn.

A report published today sets out the foundation for a proposed City AI Readiness Index, giving city governments a comparable reference point to that which national governments have used since 2017 – and giving citizens and residents a clearer picture of how prepared their city is.

"Cities are where most people deal with government, yet there has been no shared way to judge how ready they are for AI," said Richard Stirling, CEO of Oxford Insights. "Our framework will give city leaders that information, and Abu Dhabi was the right place to test it. It has assembled every layer of the AI stack, from compute and energy through models and capital to government as a large-scale user. Applying the framework to other cities then shows the different routes they are taking and what each one relies on."

City AI Readiness: A Deep Dive into Abu Dhabi and the Global Landscape was produced in collaboration with Mohamed bin Zayed University of Artificial Intelligence and Khalifa University.

It finds no single model of AI readiness and identifies areas requiring continued attention as deployment scales, including compute and energy requirements, talent, governance and resilience.

Researchers used a six-pillar framework for understanding AI readiness and identified four city archetypes that can help leaders assess strengths, gaps and priorities for future development.

They are infrastructure-led "Platform Cities", research-driven "Cognitive Cities", service-focused "Delivery Cities" and "Strategic Cities", where AI sits at the centre of government and economic planning.

Abu Dhabi was identified alongside Seoul as a Strategic City.

In January 2025, it launched a three-year strategy to transform into the world's first AI-native government.

TAMM, its agentic AI-powered public services platform used by 4.7 million, now resolves 96 per cent of enquiries autonomously through AI.

Oxford Insights plans to pilot the index across 15 to 20 cities.

About Oxford Insights

Since 2017, Oxford Insights has produced the Government AI Readiness Index — the first global AI index focused specifically on the role of government. Used by countries around the world as a benchmark, the Index features in multiple national AI strategies and informs policy making at the highest levels. Oxford Insights is a research and advisory firm specialising in government AI readiness and digital transformation.

Notes to editors

Report title: City AI Readiness: A Deep Dive into Abu Dhabi and the Global Landscape

Full report available at: https://oxfordinsights.com/city-ai-readiness-ad/

Publication date: 6 October 2026

Permalink

https://www.aetoswire.com/en/news/0610202657810

Contacts

Katie Haigh

katie.haigh@oxfordinsights.com